DAKOTA ALESSANDRINI: Open Payments
NPI 1669191540 · DYER, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,304 in 56 payments from 25 companies in 2025. Trend: 2023 $1,237 · 2024 $1,809 · 2025 $1,304
Food & beverage: $1,304
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $188 |
| ABBVIE INC. | 5 | $116 |
| E.R. Squibb & Sons, L.L.C. | 5 | $104 |
| Stryker Corporation | 2 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $70 |
| ARRAY BIOPHARMA INC | 3 | $69 |
| Astellas Pharma US Inc | 3 | $63 |
| Novartis Pharmaceuticals Corporation | 2 | $59 |
| Celgene Corporation | 2 | $50 |
| Eisai Inc. | 2 | $48 |
Products named: AUGMENT INJECTABLE, OPDIVO, EPKINLY, CALQUENCE, KISQALI, REBLOZYL, Lenvima, RYBREVANT.
Industry payments across IN — which companies pay providers there.
